OncRef

Clinical Trial: NCT04836507

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Curocell Inc.
Information Provided By:Curocell Inc.
Last Update Posted:2026-07-01

Study Overview

Brief Summary

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Official Title

An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Conditions

Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL), ALL (Acute B-Lymphoblastic Leukemia)

Intervention / Treatment

  • Biological: CRC01
  • Drug: Fludarabine
  • Drug: Cyclophosphamide

Other Study ID Numbers

  • CRC01-01

Start Date (Actual)

2021-03-02

Primary Completion Date (Estimated)

2030-08-15

Study Completion Date (Estimated)

2030-09-26

Enrollment (Estimated)

91

Study Type

Interventional

Phase

Phase 1, Phase 2